^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study

Published date:
05/14/2021
Excerpt:
AR amplification and TP53 and/or RB1 alterations were associated with resistance to abiraterone or docetaxel.
DOI:
10.6004/jnccn.2020.7663